RESTORE- serrapeptase and huperzine a gel
RESTORE- serrapeptase and huperzine a liquid United States - English - NLM (National Library of Medicine)

restore- serrapeptase and huperzine a gel restore- serrapeptase and huperzine a liquid

key origins, inc. - serrapeptase (unii: nl053abe4j) (serrapeptase - unii:nl053abe4j), huperzine a (unii: 0111871i23) (huperzine a - unii:0111871i23) - odor free nutrient rich topical gel for use with diminished cognition and the aging brain.

INVEGA HAFYERA paliperidone (as palmitate) 1000 mg in 5 mL modified release suspension for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

invega hafyera paliperidone (as palmitate) 1000 mg in 5 ml modified release suspension for injection pre-filled syringe

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1560 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

INVEGA HAFYERA paliperidone (as palmitate) 700 mg in 3.5 mL modified release suspension for injection pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

invega hafyera paliperidone (as palmitate) 700 mg in 3.5 ml modified release suspension for injection pre-filled syringe

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1092 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

KETOROLAC JUNO ketorolac trometamol 30 mg/1 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

ketorolac juno ketorolac trometamol 30 mg/1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - ketorolac trometamol, quantity: 30 mg - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections; ethanol - ketorolac trometamol solution for injection is indicated for the short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days.,it is recommended that ketorolac parenteral be used in the immediate post-operative period.,patients can then be converted to the oral formulation (dependent on their analgesic needs), as outlined in the "dosage and administration" section (refer to "conversion from parenteral to oral therapy"). the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. note that oral dosage form can be available from other brand/s.,general,ketorolac trometamol solution for injection is not recommended for use as an obstetrical pre-operative medication or for obstetrical analgesia because it has not been adequately studied for use in these circumstances and because the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and foetal circulation.,there is no satisfactory evidence for the use of ketorolac trometamol solution for injection in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid or osteoarthritis).

TRAMADOL AN tramadol hydrochloride 100 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

tramadol an tramadol hydrochloride 100 mg/2 ml solution for injection ampoule

juno pharmaceuticals pty ltd - tramadol hydrochloride, quantity: 100 mg - injection, solution - excipient ingredients: sodium acetate trihydrate; water for injections - tramadol an solution for injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Levetiracetam SUN levetiracetam 500mg/5mL concentrated injection vials Australia - English - Department of Health (Therapeutic Goods Administration)

levetiracetam sun levetiracetam 500mg/5ml concentrated injection vials

sun pharma anz pty ltd - levetiracetam, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: glacial acetic acid; water for injections; sodium chloride; sodium acetate trihydrate - levetiracetam (film-coated tablets and oral solution) is indicated for:,? use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation, ? monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. ? add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and ? add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam sun concentrated injection after dilution is an alternative for patients when oral administration is temporarily not feasible.

DBL MORPHINE SULFATE 30mg/1mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dbl morphine sulfate 30mg/1ml injection ampoule

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 30 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

DBL MORPHINE SULFATE 5mg/1mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

dbl morphine sulfate 5mg/1ml injection ampoule

pfizer australia pty ltd - morphine sulfate pentahydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - indications as at 7 july 2020: dbl morphine sulfate injection is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. dbl morphine sulfate injection may also be used as a pre-operative medication and as an analgesic adjunct in general anaesthesia.